伊立替康与奈达铂联合新辅助化疗方案治疗宫颈癌的疗效观察

Observation on Efficacy of Irinotecan and Nedaplatin Combined with Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer

目的探讨伊立替康与奈达铂联合新辅助化疗方案治疗宫颈癌的临床疗效。方法选择2016年1月至2019年5月我院收治的100例宫颈癌患者,随机分为对照组和观察组各50例。对照组直接进行根治性子宫切除术,观察组术前采用伊立替康与奈达铂联合新辅助化疗方案进行治疗,化疗结束后2~4周进行手术,术式同对照组。比较两组患者的临床疗效、手术及术后恢复情况。结果观察组的总有效率为94.00%,高于对照组的76.00%(P <0.05)。观察组的术中出血量少于对照组,手术时间、住院时间及膀胱功能恢复时间短于对照组,术后体力状况评分低于对照组,差异均有统计学意义(P <0.05)。结论伊立替康与奈达铂联合新辅助化疗方案治疗宫颈癌患者的临床疗效较好,可有效改善患者手术及术后恢复情况,值得临床推广。

Objective To explore the clinical efficacy of irinotecan and nedaplatin combined with neoadjuvant chemotherapy in the treatment of cervical cancer. Methods 100 patients with cervical cancer admitted to our hospital from January 2016 to May 2019 were selected and randomly divided into control group and observation group, with 50 cases in each group. The control group received radical hysterectomy directly. The observation group was treated with irinotecan and nedaplatin combined with neoadjuvant chemotherapy before operation. The operation was performed at 2 to 4 weeks after chemotherapy, and was the same as that of the control group. The clinical efficacy, and the operative and postoperative recovery were compared between the two groups. Results The total effective rate of the observation group was 94.00%, higher than 76.00% of the control group(P <0.05). The intraoperative blood loss of the observation group was less than that of the control group, the operation time, hospitalization time and bladder function recovery time were shorter than those of the control group, and the postoperative physical score was lower than that of the control group(all P <0.05). Conclusions Irinotecan and nedaplatin combined with neoadjuvant chemotherapy in the treatment of patients with cervical cancer has better clinical efficacy, can effectively improve patients’ operative and postoperative recovery, which is worthy of clinical promotion.